Literature DB >> 28003218

Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.

Dilip Nathwani1, Ralph Corey2, Anita F Das3, Taylor Sandison4, Carisa De Anda4, Philippe Prokocimer5.   

Abstract

In the treatment of acute bacterial skin and skin structure infections, pooled data from 2 clinical trials (N = 1333 patients) showed that programmatic and investigator-assessed early treatment success both had a high positive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients. The negative predictive value of programmatic early success was <20%. These exploratory findings require prospective real-world evaluation. CLINICAL TRIALS REGISTRATION: NCT01170221; NCT01421511.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  ABSSSI; antibacterial therapy; oxazolidinones; tedizolid; treatment outcomes.

Mesh：

Substances：

Year:  2016        PMID： 28003218     DOI： 10.1093/cid/ciw750

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.

Authors:  Claudia Ihm; Jesse D Sutton; Tristan T Timbrook; Emily S Spivak
Journal:  Open Forum Infect Dis       Date:  2019-05-07       Impact factor: 3.835

2.  Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation.

Authors:  Jesse D Sutton; Ronald Carico; Muriel Burk; Makoto M Jones; XiangMing Wei; Melinda M Neuhauser; Matthew Bidwell Goetz; Kelly L Echevarria; Emily S Spivak; Francesca E Cunningham
Journal:  Open Forum Infect Dis       Date:  2020-01-27       Impact factor: 3.835

3.  Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Authors:  Xiaoju Lv; Jeff Alder; Li Li; William O'Riordan; Michael J Rybak; Hui Ye; Ruiping Zhang; Zhongqi Zhang; Xu Zhu; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

4.  Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections.

Authors:  Mark H Wilcox; Matthew Dryden
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

5.  Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.

Authors:  Christian Eckmann; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

6.  Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series.

Authors:  Sergey Shlyapnikov; Arturo Jauregui; Nana N Khachatryan; Asok Kurup; Javier de la Cabada-Bauche; Hoe N Leong; Li Li; Mark H Wilcox
Journal:  Infect Dis Ther       Date:  2018-07-12

7.  Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.

Authors:  Carisa De Anda; Steven Anuskiewicz; Philippe Prokocimer; Jose Vazquez
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.